Introduction
The incidence of lung cancer among men and women is one of the highest among the many solid cancers, with lung cancer being the most common cause of cancer-related death worldwide [1] . Although several treatments are available for the advanced stage, they are palliative, and the cure rate remains low for patients with non-small cell lung cancer (NSCLC). Therefore, new therapeutic strategies are required to improve the poor prognosis of patients with NSCLC.
The Notch receptor is a single-pass transmembrane protein that regulates cell-fate determination in multicellular organisms. There are four Notch receptors (Notch1-4), and these bind two families of ligands, Jagged (Jagged-1, -2) and Delta-like (Dll-1, -3 and -4) [2, 3] . Upon ligand binding, the Notch receptor undergoes a number of proteolytic cleavages. The final cleavage by the γ secretase complex results in the release of the Notch intracellular domain (NICD), which forms a nuclear complex with a transcription factor and induces expression of various target genes, including the Hairy and enhancer of split (Hes) and Hairy/ enhancer of split related with YRPW (Hey) gene family [4] . Several studies have highlighted the aberrant activation of Notch pathways in tumorigenesis of many cancers [5] [6] [7] [8] .
We have demonstrated that Notch3 is expressed in approximately 40 % of NSCLC tumors and that suppression of the NICD3 protein by dominant negative or γ secretase inhibitor [gamma-secretase inhibitor (GSI)] inhibits growth of lung cancer both in vitro and in vivo [9, 10] .
Resistance to radiation is one of the major reasons for radiotherapy failure in NSCLC. We reported earlier that Notch3 and its downstream effector Hey1 were upregulated in radiated NSCLC cell lines. Therapy with GSI, when combined with radiation therapy, significantly suppressed the growth of lung cancer cells compared with either GSI or radiation therapy alone by a mechanism that possibly includes the suppression of radiation-induced Notch activation by GSI [11] . However, this radiation-induced Notch3 activation mechanism has not been clarified. We report here our attempt to clarify this mechanism through focusing on hypoxia inducible factor 1 (HIF-1). HIF-1 is a heterodimeric transcription factor composed of HIF-1α and HIF-1β. It is stabilized by hypoxia and affects many processes, such as glycolysis, mitosis and angiogenesis [12] [13] [14] [15] . Moreover, hypoxia activates Notch responsive promoters and increases the expression of NICD, which interacts with HIF-1α [16] . In this study, we hypothesized that HIF-1α is involved in radiation-induced Notch activation in NSCLC and, therefore, a HIF inhibitor (YC-1) would have an antitumor effect when combined with radiation therapy.
Methods

Cell lines and inhibitors
The NSCLC cell line H460 was obtained from the American Type Culture Collection (Manassas, VA), and the human lung cell cancer line HCC2429 was established as previously described [17] . Both the H460 and HCC2429 cell lines have been shown previously to have high Notch3 expression [18] . These cell lines were maintained in RPMI medium supplemented with 10 % fetal calf serum, at 37 °C, in a humid environment and a 5 % CO 2 atmosphere. The γ secretase inhibitor XX (GSIXX) was obtained from Calbiochem (San Diego, CA) and the HIF-inhibitor YC-1 was obtained from AG Scientific (San Diego, CA).
Hypoxic treatment
Cells were incubated in a Personal multigas incubator (ASTEC Co. Ltd., Suita, Osaka, Japan) in a humid environment, at 37 °C and in a 5 % CO 2 /1 % O 2 atmosphere. All in vitro experiments were performed under hypoxic conditions.
Antibodies and Western blotting analysis
Hypoxia inducible factor 1α (1:500; BD Biosciences, San Jose, CA) was detected using a mouse polyclonal antibody, and Notch3 was detected using a rabbit polyclonal antibody (1:500; Allele Biotechnology and Pharmaceuticals, Inc., San Diego, CA). All analyses included staining with Ponceau S, which confirmed that protein loading was equal. The band intensity was demonstrated by quantitative densitometric analysis using National Institutes of Health (NIH) Image Ver1.62 software (NIH, Bethesda, MD). Standardization was performed by measuring actin in the same blots with anti-actin antibody (A-2066; Sigma-Aldrich Corp., St. Louis, MO).
Small interfering RNA transfection
The HIF-1α small interfering RNA (siRNA) sequence is ON-TARGET + SMART pool L-004018-00, and the Notch3 siRNA sequence is ON-TARGET + SMART pool L-011093-00-0005, both obtained from Thermo Fisher Scientific (Waltham, MA). Cells were transfected with 100 nmol/L siRNA in Opti-MEM medium (Invitrogen, Carlsbad, CA) using 100 pmol Lipofectamine 2000 (Invitrogen). Non-specific siRNAs against the target sequence were used as controls.
MTT proliferation assay and combination index/ isobologram for analysis of antitumor efficacy of the combination treatment of radiation, GSI and YC-1 on radiated cancer cells
To analyze the antitumor efficacy of the combined YC-1 and radiation treatment, the cells were treated with radiation at 8 Gy and with either an increasing dose of YC-1 and radiation simultaneously or with an increasing dose of YC-1 at 24 h before or after radiation. To analyze the effect of the combined GSI and radiation treatment, GSI was administered 24 h after the cells were exposed to radiation at 8 Gy. The treated cells were then incubated for 24 h under hypoxic conditions. The MTT assay was performed according to the manufacturer's recommendation (Thermo Fisher Scientific), and the absorption of light was determined at 560 nm using a microplate reader (Varioskan Flash; Thermo Fisher Scientific). In the combination index/isobologram analysis, cells were irradiated and treated with YC-1 simultaneously; GSI was administered 24 h after the simultaneous radiation and YC-1 treatment. GSI and YC-1 were administered at a constant concentration ratio of 1:1, which was determined by IC 50 (concentration of an inhibitor where the response/binding is reduced by half) data (Fig. 3a, c) . Treated cells were then incubated for 24 h under hypoxia. The MTT assay was performed and the total cytotoxicity of GSI and YC-1 at each radiation dose was analyzed by a Fa (fraction affected)-combination index (CI) isobologram plot using the computer software Compusyn (Biosoft, Cambridge, UK) [19] .
Clonogenic assay
Cells were exposed to radiation at 4, 8 and 12 Gy, treated with increasing doses of YC-1 and then incubated under hypoxic conditions for 48 h, following which they were fixed and stained for 1 min with 0.5 % crystal violet in methanol. After staining, colonies were counted three times by the naked eye. The survival fraction was calculated as: (mean colony counts/number of cells inoculated) × plating efficiency (PE). The PE was defined as: mean colony count/ number of cells inoculated for non-irradiated controls [20] .
In vivo tumorigenicity
All animal husbandry and experiments were performed using protocols approved by the Institutional Animal Care 
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Committee at Hokkaido University School of Medicine. An aliquot of H460 cells (1.0 × 10 6 cells) was diluted in 100 μl of phosphate buffered saline and injected subcutaneously into the right posterior legs of athymic, 5-weekold, female nude mice (nu+/nu+). When the tumors were palpable, the mice were randomly assigned to a treatment group of five mice each. In the radiation-only group, the mice were exposed to 8 Gy of radiation on days 1 and 8. The radiation was administered to the tumor only, with the remainder of the body shielded with lead. In the GSIonly group, 200 μg/kg GSIXX was administered via the intraperitoneal (IP) route on days 2, 3, 4 and 9, 10, 11, as previously described [11, 18] . In the YC-1 group, 15 μg/g YC-1 was administered via the IP route on days 1 and 8, as previously described [21] . The tumors were then measured every 2 days using a digital caliper. Tumor volume (TV) was determined using the formula: (TV = length × width × height)/2 [20] . Tumor growth rate (%TV) on day X was calculated as: (TV on day X/TV on day 1) × 100, as previously described [18] . Some tumors were resected on day 15 for Western blotting analysis and immunohistochemistry.
Immunohistochemical analysis
The methods used in the immunohistochemical analysis are described in detail in the Supplementary Methods section of the Electronic Supplementary Material (ESM).
Statistical analysis
Statistical analysis was carried out using Microsoft Excel software (Microsoft Corp., Redmond, WA) and Jump (Pro 12.0.0; SAS Institute, Raleigh, NC). Significance between the control and observation arms of both in vitro and in vivo assays was determined using Student's t test, analysis of variance and the Turkey-Kramer test. Statistical significance was established at p < 0.05.
Results
Radiation-enhanced activation of the Notch pathway in lung cancer cells under hypoxic conditions
To investigate the effect of radiation on the Notch and HIF pathway under hypoxic conditions, we assessed the expression of the Notch receptors and HIF-1α after cancer cells were irradiated at varying doses and incubated under hypoxic conditions. In both the H460 and HCC2429 cell lines, HIF-1α expression was induced following incubation of the radiated cells under hypoxic conditions for 2 h and enhanced at 6 h (0 Gy), but there was only a slight increase in HIF-1α expression in radiated cells compared to the control (0 Gy) (Fig. 1a) . Moreover, vascular endothelial growth factor (VEGF), which is a target gene of HIF, was 6 cells per 6-well plate 1 day before transfection. The cells were transfected with 100 nmol/L HIF-1α siRNA in Opti-MEM medium using 100 pmol Lipofectamine 2000. The medium was exchanged after 6 h and the cells then treated with radiation at 8 Gy, followed by incubation under hypoxic conditions. Cells were harvested at 6 and 24 h after radiation. The data shown are representative results from three different experiments. C control, H siRNA targeting HIF-1α.
a The efficiency of siRNA transfection was measured using Western blotting analysis. HIF-1α expression was suppressed by siRNA at 6 h after siRNA transfection. b NICD3 was not inhibited by HIF-1α suppression without radiation treatment (0 Gy) following incubation under hypoxic conditions. Radiation-induced NICD3 activation was downregulated by HIF-1α suppression in a dose-dependent manner (4, 8, 12 Gy) at 24 h after radiation. Standardization was performed by measuring actin in the same blots with anti-actin antibody. Number under each blot (with the exception of the actin blot) represents the ratio of treated/untreated (control) protein expression H460 and HCC2429 cell lines were seeded at 6000 cells and 10,000 cells per well, respectively, into a 96-well plate and incubated overnight. Plated cells were treated with radiation at 8 Gy; GSIXX at varying doses was administered 24 h after radiation. Treated cells were then incubated for 24 h under hypoxic conditions and the MTT assay was performed. The IC 50 was less for the combined therapy than for the GSIXX alone in both cell lines. d The Fa-CI plot of isobologram analysis for GSI and YC-1 at each radiation dose. H460 and HCC2429 cells were seeded at 6000 cells and 10,000 cells per well, respectively, into a 96-well plate and incubated overnight. Cells were treated with 8 Gy radiation and YC-1 simultaneously, followed by GSI treatment 24 h after radiation and YC-1. YC-1 and GSI were administered at a constant concentration ratio (1:1), which was determined on the basis of IC 50 data of GSIXX and YC-1 (a, b). Treated cells were then incubated for 24 h under hypoxic conditions and the MTT assay performed. The combination index (CI) value tended to be <1, indicating a synergistic effect at each radiation dose. The resulting CI theorem of Chou-Talalay provides a quantitative definition for additive effect (CI = 1), synergistic effect (CI < 1) and antagonist effect (CI > 1) in drug combinations 1 3
upregulated by radiation, suggesting that the HIF downstream gene was involved (ESM Fig. S1a ). Compared to the control (0 Gy), the expression of NICD3 was upregulated in the irradiated cells after 24 h of incubation under hypoxic conditions (Fig. 1b) , whereas the expression of other Notch receptors (Notch1, 2, 4) was not affected (ESM Fig. S2 ). Radiation treatment enhanced Notch target gene Hey1 mRNA expression but not Hes1 protein expression (ESM Fig. S1b, c) .
Specific suppression of HIF-1α by siRNA ameliorated radiation-induced Notch activation under hypoxic conditions
To examine whether HIF-1α was involved in radiationinduced Notch expression under hypoxic conditions, we specifically suppressed HIF-1α expression prior to irradiation of the cells using siRNA and then evaluated the effect of this specific suppression of HIF-1α on the radiation-induced Notch pathway. HIF-1α was inhibited by siRNA at 6 h after radiation (Fig. 2a) . We found that HIF-1α suppression did not inhibit NICD3 under hypoxic conditions in the absence of radiation (0 Gy), while NICD3 activation (Fig. 2b) and Hey1 mRNA expression (ESM Fig. S3b ) was downregulated by HIF-1α suppression at 24 h after radiation under hypoxic conditions. HIF-1α inhibition did not affect the expression of other Notch receptors (ESM Fig. S3a ).
Concurrent treatment with YC-1 and radiation-enhanced growth inhibition of lung cancer in vitro
Inhibitors of HIF are reported to be radiosensitizers [22, 23] ; as such, the efficacy of YC-1, a HIF inhibitor, with radiation depends on the treatment schedule [24] . Figure 3b shows that based on the results of the clonogenic assay colony formation was not suppressed by radiation at 4 Gy and that >8 Gy of radiation was needed to suppress. We therefore used radiation at 8 Gy to test irradiated cells in combination with other treatments. To determine whether combining YC-1 and radiation can inhibit the growth of NSCLC cell lines, as well as to identify which treatment schedule enhances radiosensitivity, we subjected H460 and HCC2429 cells to irradiation at 8 Gy and treatment with YC-1 at varying doses. Cell viability was determined using the MTT assay. When YC-1 was administered simultaneously with radiation under hypoxic conditions, in both cells lines there was a significant decrease in the IC 50 of YC-1 compared with the treatment with YC-1 alone (0 Gy). In contrast, sequential treatment had no significant impact on the IC 50 of YC-1 compared with treatment with YC-1 alone (0 Gy) (Fig. 3a) . To confirm these results, we performed a clonogenic assay, which showed that this concurrent treatment schedule resulted in a greater suppression in colony formations compared with radiation only (Fig. 3b ).
Sequential treatment with GSI after radiation-enhanced growth inhibition of lung cancer in vitro
We have previously reported that the antitumor effect of GSI and radiation was more effective when GSI was administered 24 h after radiation under normoxic conditions [11] . To evaluate whether this sequential treatment schedule also inhibits cell proliferation under hypoxic conditions, H460 and HCC2429 cells were treated with GSIXX at various doses after being exposed to 8 Gy of radiation; cell viability was determined using the MTT assay. Sequential treatment was found to reduce the IC 50 of GSIXX compared with treatment with GSIXX alone (0 Gy) (Fig. 3c) .
Combination of GSI and YC-1 had a synergistic antitumor effect when cells were irradiated under hypoxic conditions in vitro
To investigate the combined antitumor effect of GSI, YC-1 and radiation, we treated the cell with GSI 24 h after simultaneous treatment with YC-1 and 8 Gy radiation; the doses were based on our previous and current findings. The Fa-CI plot of isobologram analysis for GSI and YC-1 at 0 (control) and 8 Gy radiation revealed that the CI value was <1. The CI theorem of Chou-Talalay defines a synergistic effect in a drug combination as a CI of <1, thereby indicating that Standardization was performed by measuring actin in the same blots with anti-actin antibody. Number under each blot (with the exception of the actin blot) represents the ratio of treated/untreated (control) protein expression. a NICD3 expression was downregulated slightly by GSI, YC-1 or the combination treatment under hypoxic conditions without radiation. The combination treatment of GSI and YC-1 showed the greatest inhibition of radiation-induced NICD3 upregulation compared with either single treatment. b HIF-1α expression was not upregulated by radiation compared with the control (0 Gy). YC-1 administration inhibited HIF-1α expression with and without radiation in both cell lines. c H460 was seeded at 1.0 × 10 6 cells per 6-well plate the day before transfection and the cells were transfected with HIF-1α siRNA or non-specific siRNAs and treated with radiation at 8 Gy. These cells were then incubated for 24 h and transfected with NICD3 siRNA or non-specific siRNAs. The cells were harvested at 24 h after transfection with NICD3 siRNA. Specific suppression of both HIF-1α and NICD3 using siRNAs significantly prevented radiation-induced NICD3 activation ▸ the combination of GSI and YC-1 had a synergistic effect at 0 and 8 Gy radiation (Fig. 3d) .
Administration of GSI and YC-1 ameliorated radiation-induced NICD3 upregulation
In a previous study we showed that radiation-induced Notch activation has a potential radioprotective role and that GSI prevents this activation under normoxic conditions [11] . We thus examined the effect of the combination treatment of GSI and YC-1 on radiation-induced Notch and HIF pathway expression under hypoxic conditions using Western blotting analysis. Cells were treated simultaneously with 8 Gy radiation and YC-1 (30 μM in H460 cells and 50 μM in HCC2429 cells). GSIXX (30 μM in H460 cells and 50 μM in HCC2429 cells) was administered 24 h after the simultaneous radiation and YC-1 treatment. These cells were then incubated for another 24 h under hypoxic conditions and harvested. When the cells were irradiated under hypoxic conditions, GSI or YC-1 downregulated radiationinduced NICD3 activation in both cell lines, and the combination of GSI and YC-1 significantly prevented radiation-induced NICD3 activation compared with the single treatment (Fig. 4a) . YC-1 administration inhibited HIF-1α more than the GSI treatment, with and without radiation, in both cell lines (Fig. 4b) . Specific suppression of HIF-1α and NICD3 using siRNAs was also performed. Similar to the treatment with GSI and YC-1, specific suppression of both HIF-1α and NICD3 significantly impaired radiationinduced NICD3 activation (Fig. 4c) . 
Combination treatment of GSI and YC-1 enhanced radiosensitivity in vivo
To examine whether the combination treatment of GSI and YC-1 enhanced radiosensitivity in vivo, we utilized a xenograft model. The scheduling of GSI, YC-1 and radiation was as outlined in Fig. 5a based on our in vitro findings and our previous findings [11, 21] . We noted a significant delay in tumor growth with the combination of GSI, YC-1 and radiation compared with other treatments (Fig. 5b) . No body weight loss was encountered (data not shown), indicating that all treatments, including the combination therapy, was well tolerated.
Combination of GSI, YC-1 and radiation has the greatest suppression of NICD3 and HIF-1α
Some tumors were resected on day 15 for molecular analysis. GSI or YC-1 downregulated NICD3 expression slightly in non-radiated cells compared with control (Fig. 5c ). The expression of NICD3 was enhanced in tumors treated with radiation, and this activation was mitigated significantly by the addition of GSI and YC-1 compared with the single treatment, which is consistent with the in vitro findings (Fig. 5c ). Immunohistochemical analysis for the expression of Notch3 protein showed that the radiationinduced Notch3 upregulation of tumors was significantly suppressed more strongly when GSI and YC-1 were administered (p < 0.05) (Fig. 5d) . The expression of HIF-1α protein also showed that additional treatment with YC-1 or a combination treatment of GSI and YC-1 suppressed radiation-induced HIF-1α upregulation (p < 0.05) (Fig. 5e ).
Discussion
It is important to understand the mechanisms of radiation resistance and to develop new strategies to improve radiation-induced tumor cytotoxicity. We have previously reported that NICD3 is upregulated in irradiated cells of the NSCLC cell line and that GSI, in combination with radiation therapy, significantly suppresses NICD3 expression and the growth of lung cancer cells [11] . These results suggest that activation of this oncogenic pathway is involved in radiation resistance. However, the mechanism of NICD3 upregulation and subsequent resistance to radiation is not fully understood.
Hypoxia is a major cause of radioresistance [15, 25] , and HIF also plays an important role in hypoxia-related resistance to radiation [14, 26] . The association between the Notch pathway and HIF-1α has been reported to be important for the invasion, proliferation and metastasis of several cancers under hypoxic conditions [27] [28] [29] [30] . HIF-1α activates the Notch pathway by interacting with and stabilizing NICD in glioblastoma and medulloblastoma under hypoxic conditions [31] . However, no studies have examined whether the relationship between the Notch pathway and HIF affects the radiation treatment. Our results show that specific suppression of HIF-1α by siRNA did not influence the Notch pathway in the absence of radiation, but it did prevent radiation-induced Notch pathway activation under hypoxic conditions, indicating that the Notch pathway is activated through HIF-1α upon radiation treatment.
However, we did not detect direct binding between NICD3 and HIF-1α when cells were treated with radiation, based on the results of the immunoprecipitation assay (data not shown). HIF-1α activates genes related to angiogenic factors, glycolytic enzymes and glucose transporters [32] [33] [34] . It has been reported that VEGF, which is a target gene for HIF signaling, increases the expression of DLL4, which is a ligand of the Notch pathway and, in turn, upregulates Notch expression, leading to productive Notch signaling [35] [36] [37] . Moreover, Snail and Slug, which induces epithelial mesenchymal transition (EMT), have been reported to be involved in the interaction between Notch and HIF under hypoxic conditions [29, 30] . These results indicate that an alternative mechanism, such as VEGF or EMT, may modulate activation of the radiation-induced Notch pathway. Fig. 5 The combination of GSI and YC-1 treatment enhanced radiosensitivity and suppressed radiation-induced Notch3 and HIF-1α expression in vivo. a Time line of treatment schedule in vivo. Aliquots of the H460 cell line (1 × 10 6 cells) were inoculated subcutaneously into the right posterior legs of nude mice. Treatment was initiated when the tumors were palpable. Mice were treated with 200 μg/kg GSIXX injected intraperitoneally 3 days per week after 8 Gy of radiation and 15 μg/g YC-1 once a week. Tumor size was measured every 2 days. RT Radiation (8 Gy). b Treatment with radiation, GSI and YC-1 resulted in a significant delay of tumor growth, compared with the control or other treatments. Results are given as the mean ± standard deviation (SD; n = 5). c The expression of NICD3 was examined by Western blotting analysis. GSI slightly inhibited NICD3 expression compared with the control treatment under hypoxic conditions without radiation. NICD3 expression was upregulated in irradiated tumors. This upregulation was mitigated, compared with the single treatment, by the addition of GSI and YC-1. Numbers under each blot represents ratios of treated/untreated (control) protein expression. con Control, R Radiation treatment, G GSI treatment, Y YC-1 treatment. d Notch3-positive tumor cells were counted under high magnification (400×) in three random and nonoverlapping fields (100 tumor cells per field). Notch3 expression was upregulated in tumors treated with radiation (81 %) compared with the control (62 %). This upregulation was impaired by the addition of GSI and YC-1 (47 %). Results are the mean ± SD (n = 3). e HIF-1α-positive tumor cells were counted under high magnification (400×) in three random and non-overlapping fields (100 tumor cells per field). HIF-1α expression tended to be upregulated with radiation (80 %) compared with the control (74 %). YC-1 or GSI and YC-1 inhibited radiation-induced HIF-1α upregulation by 72 and 68 %, respectively. Results are the mean ± SD (n = 3) ◂ The solid tumor environment contains hypoxic lesions which are a major cause of radioresistance. Therefore, we considered that our experimental design could mimic the actual cancer environment and overcome resistance to radiotherapy under hypoxia. We found that the efficacy of the combination therapy was highly dependent on the treatment schedule, which is in agreed with our previous data and other results from other studies [11, 24] . In clinical settings, we may have to consider the treatment schedule as follows: first the administration of radiation and HIF-1 inhibitor, followed by GSI administration in patients with NSCLC.
In summary, our data provide evidence that HIF-1α is associated with radiation-dependent NICD3 activation and that the addition of GSI and HIF inhibitor to the radiation treatment enhanced the cytotoxicity of radiation in lung cancer. Although further studies are needed to confirm our hypothesis, this study provides compelling evidence that combining HIF inhibitor, GSI and radiation represents a rational strategy for the treatment of patients with NSCLC.
